Search by Drug Name or NDC
NDC 31722-0509-60 Zidovudine 300 mg/1 Details
Zidovudine 300 mg/1
Zidovudine is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Camber Pharmaceuticals, Inc.. The primary component is ZIDOVUDINE.
MedlinePlus Drug Summary
Zidovudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Zidovudine is given to HIV-positive pregnant women to reduce the chance of passing the infection to the baby. Zidovudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although zidovudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 31722-0509-60Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Zidovudine
Product Information
| NDC | 31722-0509 |
|---|---|
| Product ID | 31722-509_fbbb4305-5ef7-b4b5-e053-6294a90a278c |
| Associated GPIs | 12108085000330 |
| GCN Sequence Number | 026550 |
| GCN Sequence Number Description | zidovudine TABLET 300 MG ORAL |
| HIC3 | W5J |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NUCLEOSIDE ANALOG, RTI |
| GCN | 44533 |
| HICL Sequence Number | 004185 |
| HICL Sequence Number Description | ZIDOVUDINE |
| Brand/Generic | Generic |
| Proprietary Name | Zidovudine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Zidovudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 300 |
| Active Ingredient Units | mg/1 |
| Substance Name | ZIDOVUDINE |
| Labeler Name | Camber Pharmaceuticals, Inc. |
| Pharmaceutical Class | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA090092 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 31722-0509-60 (31722050960)
| NDC Package Code | 31722-509-60 |
|---|---|
| Billing NDC | 31722050960 |
| Package | 12 BOTTLE in 1 CASE (31722-509-60) / 60 TABLET in 1 BOTTLE |
| Marketing Start Date | 2008-04-25 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |